Latest News
Circassia's ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune® cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.
25 February 2013
Circassia Receives Outstanding Abstract Awards at 2012 World Allergy Organization International Scientific Conference
10 December 2012
Circassia Appoints Dr Jean-Jacques Garaud to its Board of Directors
06 December 2012
Circassia Initiates Pivotal Phase 3 ToleroMune® Trial in Cat Allergen-Induced Rhinoconjunctivitis
04 October 2012
Did you know?
The average bed could be home to up to 1.5 million house dust mites